Background Image
Table of Contents Table of Contents
Previous Page  66 / 66
Information
Show Menu
Previous Page 66 / 66
Page Background

REGOVAL 80, 160 mg.

Each tablet contains 80, 160 mg valsartan respectively. S3 A43/7.1.3/0548, 0549. For full prescribing information, refer to the professional information approved by SAHPRA, October 2019.

REGOVAL CO 80/12,5, 160/12,5, 160/25 mg.

Each tablet contains 80, 160, 160 mg valsartan respectively and 12,5, 12,5, 25 mg hydrochlorothiazide respectively. S3 A44/7.1.3/0018, 0019, 0020.

For full prescribing information, refer to the professional information approved by SAHPRA, September 2019.

1)

Williams B,

et al.

2018 ESC/ESH guidelines for the management of arterial hypertension.

Journal of Hypertension

2018;36:1953-2041.

2)

Black HR,

et al.

Valsartan, more than a decade of experience.

Drugs

2009;69(17):2393-2414.

RGLB703/01/2021.

For further product information contact

PHARMA DYNAMICS

P O Box 30958 Tokai Cape Town 7966

Fax

+27 21 701 5898

Email

info@pharmadynamics.co.za

CUSTOMER CARE LINE

0860 PHARMA (742 762) / +27 21 707 7000

www.pharmadynamics.co.za

ELEVATED BP IS A RISK FACTOR FOR:

1

• myocardial infarction

• heart failure

• stroke and renal disease

VALSARTAN HAS:

2

• proven e cacy in a broad range of patients

• a placebo-like side e ect profile for common adverse events

CONVENIENTLY PACKED IN

30

TABLETS.

REDUCE THE RIPPLE EFFECT

NEW

INTRODUCING OUR

VALSARTAN

RANGE